Repare Therapeutics (NASDAQ:RPTX – Get Free Report) was upgraded by equities researchers at Bloom Burton from an “accumulate” rating to a “buy” rating in a research note issued on Friday, Zacks.com reports.
Separately, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Repare Therapeutics in a report on Wednesday, February 21st.
Check Out Our Latest Research Report on Repare Therapeutics
Repare Therapeutics Stock Performance
Repare Therapeutics (NASDAQ:RPTX – Get Free Report) last issued its earnings results on Wednesday, February 28th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.11). The firm had revenue of $13.05 million during the quarter, compared to analysts’ expectations of $15.92 million. Repare Therapeutics had a negative net margin of 183.43% and a negative return on equity of 39.82%. As a group, equities analysts expect that Repare Therapeutics will post -2.74 earnings per share for the current year.
Hedge Funds Weigh In On Repare Therapeutics
Institutional investors have recently modified their holdings of the company. Deutsche Bank AG acquired a new position in shares of Repare Therapeutics in the fourth quarter valued at approximately $40,000. Wells Fargo & Company MN raised its position in shares of Repare Therapeutics by 185.8% in the fourth quarter. Wells Fargo & Company MN now owns 3,041 shares of the company’s stock valued at $45,000 after buying an additional 1,977 shares during the last quarter. Barclays PLC purchased a new stake in Repare Therapeutics in the second quarter valued at approximately $36,000. UBS Group AG grew its holdings in Repare Therapeutics by 26.3% in the third quarter. UBS Group AG now owns 3,551 shares of the company’s stock valued at $43,000 after purchasing an additional 739 shares during the period. Finally, SRS Capital Advisors Inc. purchased a new stake in Repare Therapeutics in the first quarter valued at approximately $49,000. Institutional investors and hedge funds own 85.09% of the company’s stock.
About Repare Therapeutics
Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.
Recommended Stories
- Five stocks we like better than Repare Therapeutics
- What to Know About Investing in Penny Stocks
- MarketBeat Week in Review – 4/15 – 4/19
- Airline Stocks – Top Airline Stocks to Buy Now
- Comprehensive Analysis of PayPal Stock
- How to Choose Top Rated Stocks
- Intuitive Surgical Stock Can Trend Much Higher This Year
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.